Arunabio

Arunabio is a biotechnology company that develops a neural exosome platform for designing therapeutics to treat neurodegenerative diseases. The company platform develops neural exosomes that can cross the blood-brain barrier and enhance the body anti-inflammatory, self-repair, and protective mechanisms to treat a range of neurodegenerative conditions. By leveraging exosome biology, Arunabio aims to deliver therapeutic payloads directly to the brain, overcoming one of the most significant challenges in neurology drug development. The platform technology enables the development of treatments for conditions such as Alzheimer disease, Parkinson disease, and other neurodegenerative disorders where blood-brain barrier penetration is essential for therapeutic efficacy. Founded in 2003 and headquartered in Athens, Georgia, the company has raised approximately $33.1 million through Series B funding from investors including Eshelman Ventures, NIH, HHS, Georgia Research Alliance, and GRA Venture Fund.